Bacterial Pneumonia: Alveolar Consolidation, Exudation, and Systemic Inflammation

Core Idea

Bacterial pneumonia causes neutrophilic infiltration and fibrinous exudation in alveoli, creating consolidation and impairing gas exchange. Systemic inflammation from bacterial virulence factors and leukocyte mediators can trigger sepsis, shock, and ARDS if widespread or in high-risk hosts.

Explainer

The lung's normal function depends on alveoli remaining open, thin-walled, and fluid-free so that oxygen and carbon dioxide can diffuse efficiently across the alveolar membrane. You know from the respiratory system that alveoli are lined by type I and type II pneumocytes and are served by an extensive capillary network. Bacterial pneumonia disrupts this architecture through the same acute inflammatory cascade you studied in general pathophysiology—but localized to a structure where inflammation is directly incompatible with function.

When bacteria (most commonly *Streptococcus pneumoniae*, but also *Klebsiella*, *Legionella*, and others) reach the alveoli, pattern recognition receptors on resident macrophages initiate the inflammatory response. Cytokines (IL-1, IL-6, TNF-α) recruit neutrophils from capillaries. Vasodilation and increased vascular permeability—the same vascular changes at the core of acute inflammation—cause plasma proteins, including fibrin, to leak into the alveolar space. This fibrinous exudate, mixed with neutrophils, cellular debris, and bacteria, fills the air sacs. On chest X-ray this appears as opacification; pathologically it is called consolidation—alveoli that should contain air now contain solid inflammatory material.

Consolidation impairs gas exchange in two ways. First, oxygen cannot diffuse across an exudate-filled alveolus. Second, blood still flows to consolidated segments (the capillaries are intact), creating a ventilation-perfusion (V/Q) mismatch: blood is "shunted" past alveoli that are not exchanging gas and arrives in the pulmonary veins with low oxygen content. The result is hypoxemia even when the patient is breathing room air. The degree of hypoxemia tracks roughly with the extent of consolidation across the lung.

Systemically, inflammatory mediators that drive alveolar inflammation also enter the bloodstream. Fever, leukocytosis, and elevated acute-phase reactants are expected systemic signs. In severe cases—particularly with virulent organisms or immunocompromised hosts—this systemic response amplifies into sepsis: a dysregulated host response causing organ dysfunction remote from the primary infection site. The lung itself can progress to ARDS if inflammation spreads broadly, destroying the alveolar-capillary barrier across large areas. Treatment therefore targets both the infectious agent (antibiotics matched to the causative organism) and the downstream complications of the inflammatory response (supportive oxygenation, hemodynamic support, prevention of secondary complications).